Edition:
United Kingdom

People: CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
18 Apr 2019
Change (% chg)

$0.01 (+1.28%)
Prev Close
$0.55
Open
$0.56
Day's High
$0.57
Day's Low
$0.55
Volume
14,532
Avg. Vol
25,784
52-wk High
$2.02
52-wk Low
$0.35

Curtis, Eric 

Mr. Eric L. Curtis is President, Chief Operating Officer of the company. Mr. Curtis also serves as the Chief Executive Officer of our wholly-owned subsidiary, Centurion BioPharma Corporation. He brings 25 years of life science leadership experience, with oncology and orphan diseases his specialty. Mr. Curtis was instrumental in the US and global development and commercialization of many successful drugs, including Votrient®, Doxil®, Velcade®, Benlysta®, Tykerb® and Adempas®. Prior to joining CytRx, Mr. Curtis served as President, U.S. Commercial at Aegerion Pharmaceuticals (now Novelion Therapeutics), Vice President and General Manager – Rare Disease/Cardiopulmonary Business Unit at Bayer Healthcare, and in positions of increasing responsibility at GlaxoSmithKline, culminating in his role as Vice President, Marketing and Global Commercial Leader. Mr. Curtis earned a Master of Business Administration degree from Pennsylvania State University and holds a Bachelor of Science degree from the University of Pittsburgh, where he double-majored in Business and Psychology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --